Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).

Autor: Toorop AA; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands a.toorop@amsterdamumc.nl., van Lierop ZY; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., Gelissen LM; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., Hoitsma E; Department of Neurology, MS Center, Alrijne Hospital, Leiden, The Netherlands., Zeinstra EM; Department of Neurology, Isala, Meppel, The Netherlands., van Rooij LC; Department of Neurology, Maasstad Hospital, Rotterdam, The Netherlands., van Munster CE; Department of Neurology, Amphia Hospital, Breda, The Netherlands., Vennegoor A; Department of Neurology, Flevoziekenhuis, Almere, The Netherlands., Mostert JP; Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands., Wokke BH; Department of Neurology, ErasMS, Erasmus Medical Center, Rotterdam, The Netherlands., Kalkers NF; Department of Neurology, OLVG Hospital, Amsterdam, The Netherlands., Hoogervorst EL; Department of Neurology, St Antonius Hospital, Utrecht, Netherlands., van Eijk JJ; Department of Neurology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., Roosendaal CM; Department of Neurology, Slingeland Hospital, Doetinchem, The Netherlands., Kragt JJ; Department of Neurology, Reinier de Graaf Hospital, Delft, The Netherlands., Eurelings M; Department of Neurology, Spaarne Gasthuis, Haarlem, The Netherlands., van Genugten J; Department of Neurology, Ziekenhuisgroep Twente, Almelo, The Netherlands., Nielsen J; Department of Neurology, Ommelander Hospital Groningen, Scheemda, The Netherlands., Sinnige L; Department of Neurology, Medical Center Leeuwarden, Leeuwarden, The Netherlands., Kloosterziel ME; Department of Neurology, Wilhelmina Hospital Assen, Assen, The Netherlands., Arnoldus EP; Department of Neurology, Elisabeth TweeSteden Hospital, Tilburg, The Netherlands., van Dijk GW; Department of Neurology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., Bouvy WH; Department of Neurology, Diakonessenhuis Hospital, Utrecht, The Netherlands., Wessels MH; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., Boonkamp L; Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Strijbis EM; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., van Oosten BW; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., De Jong BA; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., Lissenberg-Witte BI; Department of Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Barkhof F; Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.; Queen Square MS Centre, Department of Neuroinflammation, Faculty of Brain Sciences, University College London Hospitals and National Institute for Health Research, London, UK., Moraal B; Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., Teunissen CE; Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Rispens T; Diagnostic Services and Immunopathology, Sanquin Research, Amsterdam, The Netherlands.; Department of Immunopathology, Landsteiner Laboratory, University of Amsterdam, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands., Uitdehaag BM; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., Killestein J; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands., van Kempen ZL; MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.

Publikováno v: Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2024 Apr 12; Vol. 95 (5), pp. 392-400. Date of Electronic Publication: 2024 Apr 12.

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.

Autor: van Lierop ZY; Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands., Noteboom S; Department of Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands., Steenwijk MD; Department of Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands., van Dam M; Department of Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands., Toorop AA; Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands., van Kempen ZL; Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands., Moraal B; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands., Barkhof F; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands/Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London, UK., Uitdehaag BM; Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands., Schoonheim MM; Department of Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands., Teunissen CE; Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands., Killestein J; Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 Dec; Vol. 28 (14), pp. 2231-2242. Date of Electronic Publication: 2022 Sep 03.

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.

Autor: van Lierop ZY; Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands., Wieske L; Department of Neurology and Neurophysiology, Amsterdam UMC, Academisch Medisch Centrum, Amsterdam Neuroscience, Amsterdam, The Netherlands., Koel-Simmelink MJ; Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam, Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam, The Netherlands., Chatterjee M; Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam, Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam, The Netherlands., Dekker I; Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands/Department of Rehabilitation Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Leurs CE; Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands., Willemse EA; Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam, Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam, The Netherlands., Moraal B; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands., Barkhof F; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands/Institutes of Neurology and Healthcare Engineering, University College London, London, UK., Eftimov F; Department of Neurology and Neurophysiology, Amsterdam UMC, Academisch Medisch Centrum, Amsterdam Neuroscience, Amsterdam, The Netherlands., Uitdehaag BM; Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands., Killestein J; Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands., Teunissen CE; Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam, Neurochemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam, The Netherlands.

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 Jan; Vol. 28 (1), pp. 102-110. Date of Electronic Publication: 2021 Apr 23.